CN110934971A - Composition with digestion promoting function and preparation method and application thereof - Google Patents
Composition with digestion promoting function and preparation method and application thereof Download PDFInfo
- Publication number
- CN110934971A CN110934971A CN201911229074.1A CN201911229074A CN110934971A CN 110934971 A CN110934971 A CN 110934971A CN 201911229074 A CN201911229074 A CN 201911229074A CN 110934971 A CN110934971 A CN 110934971A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- food
- test
- malt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 230000029087 digestion Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 29
- 241000132012 Atractylodes Species 0.000 claims abstract description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 19
- 241001092040 Crataegus Species 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 235000019202 steviosides Nutrition 0.000 claims description 13
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 229940013618 stevioside Drugs 0.000 claims description 12
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 229960004106 citric acid Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 241001038563 Pseudostellaria Species 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 235000021552 granulated sugar Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 13
- 230000001055 chewing effect Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 6
- 235000019658 bitter taste Nutrition 0.000 abstract description 3
- 235000009508 confectionery Nutrition 0.000 abstract description 3
- 235000019606 astringent taste Nutrition 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 57
- 238000011156 evaluation Methods 0.000 description 28
- 239000007910 chewable tablet Substances 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 18
- 229940068682 chewable tablet Drugs 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000001953 sensory effect Effects 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 230000030136 gastric emptying Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000030135 gastric motility Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000021195 test diet Nutrition 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- -1 decoction Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000001962 taste-modifying agent Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021071 low fiber diet Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a composition with digestion promoting function, which is characterized by comprising the following components in parts by weight: 1-10 parts of hawthorn, 1-15 parts of malt, 1-10 parts of bighead atractylodes rhizome, 1-15 parts of dried orange peel and 1-10 parts of radix pseudostellariae. According to the invention, through multiple experimental researches, types, proportions and dosage proportions of auxiliary materials are preferably obtained, so that the problem of bitter and astringent taste after the chewing tablet prepared from the traditional Chinese medicine extract is usually eaten, namely, the chewing tablet does not feel greasy, and the prepared tablet has good chewing feeling, is sour, sweet, delicious and attractive in appearance. In addition, the tablet prepared from the composition has the health-care function of promoting digestion proved by human body function experiments.
Description
Technical Field
The invention relates to the field of medicines or health-care foods, in particular to a composition with a digestion promoting and health-care function and a preparation method and application thereof.
Background
Modern people are under heavy stress, are nervous, have irregular working and life, often eat one meal and full one meal, have high fat, high protein and low fiber diet and increased drinking amount, have high incidence of digestive system diseases, and almost half of patients in clinic diagnosis in various medical institutions belong to the digestive system according to incomplete statistics.
Dyspepsia refers to a group of clinical syndromes which have uncomfortable symptoms such as epigastric pain, epigastric distension, early satiety, eructation, inappetence, nausea, vomiting and the like, and organic diseases causing the symptoms are eliminated through examination, and the symptoms of dyspepsia can continuously or repeatedly attack, and is the most common functional gastrointestinal disease in clinic. Dyspepsia belongs to the categories of symptoms such as fullness, stomachache and epigastric upset in the traditional Chinese medicine, and the disease is in the stomach, relates to organs such as liver and spleen, and is suitable for treatment based on syndrome differentiation, strengthening spleen and stomach, soothing liver and regulating qi, promoting digestion and removing food stagnation and the like.
Disclosure of Invention
The invention aims to provide a composition with dual purposes of medicine and food and having the function of promoting digestion, and simultaneously provides a chewable tablet preparation based on the composition, and solves the problems that the general chewable tablet containing traditional Chinese medicine components has poor taste and chewing feeling, insufficient friability can not meet the requirement and the like by screening auxiliary material diluents, flavoring agents and the like.
Specifically, the invention provides a composition with digestion promoting function, which comprises the following components in percentage by weight: 1-10 parts of hawthorn, 1-15 parts of malt, 1-10 parts of bighead atractylodes rhizome, 1-15 parts of dried orange peel and 1-10 parts of radix pseudostellariae. The composition of the present invention may be directly ground into powder, or may be an extract prepared by a conventional method in the art, etc. The traditional Chinese medicine used in the composition of the present invention can also be used by directly grinding into powder, extract or other processing forms.
In another embodiment of the present invention, the composition comprises by weight: 3-7 parts of hawthorn, 3-7 parts of malt, 3-7 parts of bighead atractylodes rhizome, 1-5 parts of dried orange peel and 1-5 parts of radix pseudostellariae.
In another embodiment of the present invention, the Chinese medicinal composition comprises, by weight: 4-6 parts of hawthorn, 4-6 parts of malt, 4-6 parts of bighead atractylodes rhizome, 1-3 parts of dried orange peel and 1-3 parts of radix pseudostellariae.
In another embodiment of the present invention, the Chinese medicinal composition comprises, by weight: 5 parts of hawthorn, 5 parts of malt, 5 parts of bighead atractylodes rhizome, 2 parts of dried orange peel and 2 parts of radix pseudostellariae.
The invention also provides application of the composition in preparing a medicament, a health-care product or food with the function of promoting digestion.
The invention also provides a medicament, health-care product or food comprising the composition as described in any one of the preceding items.
In another embodiment of the present invention, the pharmaceutical, health product or food can be in the form of oral, topical or injectable administration, such as capsule, tablet, granule, decoction, pill, oral liquid, tincture, syrup, suppository, gel, spray or injection; optionally chewable tablets.
In another embodiment of the present invention, the pharmaceutical, health product or food comprises pharmaceutically or dietetically acceptable excipients; examples of such compounds include sucrose, mannitol, sorbitol, dextrin, magnesium stearate, lactose, microcrystalline cellulose, starch, white sugar, xylitol, sucralose, and steviol glycosides.
In another embodiment of the present invention, in the medicine, health product or food, the composition may be prepared into extract powder, and the mass ratio of the extract powder to the auxiliary material is preferably 10: 1-5, more preferably 10: 3.5.
in another embodiment of the present invention, the pharmaceutical, nutraceutical or food additive is selected from microcrystalline cellulose, stevioside, citric acid and magnesium stearate.
As a preferred embodiment, the weight ratio of the composition, the microcrystalline cellulose, the stevioside, the citric acid and the magnesium stearate is preferably 50-70: 10-50: 0.5-2: 1-5: 0.5 to 2, more preferably 56 or 40: 1: 2: 1.
the invention also provides a preparation method of the composition, which comprises the steps of adding water into hawthorn, malt, bighead atractylodes rhizome, dried orange peel and radix pseudostellariae according to the proportion, decocting, filtering, and spray-drying the concentrated solution.
In another specific embodiment of the invention, the adding amount of the water is 10 times of the weight of the medicinal materials, and the decocting and extracting times are 2 times and 1 hour each time.
In another specific embodiment of the invention, the concentrated solution is concentrated under reduced pressure at 70 +/-5 ℃ until the relative density is 1.1-1.15 (60 +/-5 ℃), and the concentrated solution is subjected to spray drying and sieving (80 meshes) to obtain dry extract powder.
The invention also provides a preparation method of the medicine, the health-care product or the food, which is characterized in that when the medicine, the health-care product or the food is a tablet, the preparation method comprises the following steps:
weighing 5 parts of hawthorn, 5 parts of malt, 5 parts of bighead atractylodes rhizome, 2 parts of radix pseudostellariae and 2 parts of dried orange peel according to the formula, adding 10 times of water, decocting and extracting for 2 times, each time for 1 hour, filtering, combining extracting solutions, concentrating under reduced pressure at 70 +/-5 ℃, concentrating to relative density of 1.8-1.12 at 60 +/-5 ℃, spray drying, crushing spray-dried powder, and sieving by a 80-mesh sieve to obtain dry paste powder;
mixing the dry extract powder with 2% citric acid, 1% stevioside and 40% microcrystalline cellulose, making soft mass with 90% ethanol, granulating with 16 mesh sieve, drying, grading, adding 1% magnesium stearate into the obtained granule, mixing, and tabletting.
In another embodiment of the present invention, when the pharmaceutical, health product or food is a tablet, such as a chewable tablet, the preparation method thereof comprises:
(1) weighing the raw medicinal materials according to a proportion, adding 10 times of water for decocting and extracting for 2 times, each time for 1 hour, filtering, combining extracting solutions, concentrating under reduced pressure at 70 +/-5 ℃, and concentrating to relative density of 1.1-1.15 (60 +/-5 ℃). Spray drying to obtain dry extract powder;
(2) mixing the above ⑴ dried powders with appropriate amount of diluent and correctant to make soft mass.
(3) Sieving the prepared soft material with 16 mesh sieve, and controlling the water content of the granules below 5.0% at the temperature of 60 + -5 ℃;
(4) granulating with 16 mesh sieve, adding lubricant, and mixing with the granules;
(5) compressing to obtain plain tablet.
(6) And (6) bottling.
The invention provides a composition for promoting digestion and a preparation method thereof, wherein hawthorn, malt, bighead atractylodes rhizome, dried orange peel and radix pseudostellariae are used as main raw materials, medicinal auxiliary materials meeting the requirements in Chinese pharmacopoeia or food additives in GB2760 are added to prepare tablets, the tablets are convenient to take and carry, and the problems that the compliance of a user is poor due to poor taste and the friability cannot meet the requirements of the pharmacopoeia when the traditional Chinese medicine extract is prepared into chewable tablets are solved.
The hawthorn, the malt, the bighead atractylodes rhizome, the dried orange peel and the radix pseudostellariae in the invention are medicinal and edible health food raw materials published by Ministry of health, and the five traditional Chinese medicines of the hawthorn, the malt, the bighead atractylodes rhizome, the dried orange peel and the radix pseudostellariae in the formula have no incompatibility of eighteen antagonisms and nineteen incompatibilities, so that the safety of the product is ensured without toxic and side effects. The hawthorn fruit in the prescription is used for treating food retention and gastric cavity fullness; the malt can promote qi circulation and promote digestion, invigorate the spleen and stimulate the appetite, contains amylase and vitamin B, and is good at digesting the five-cereal rice flour; the dried orange peel is a traditional Chinese medicine for regulating qi, can invigorate spleen and regulate qi, and is used for treating abdominal distension, anorexia, vomiting and diarrhea; radix pseudostellariae can tonify middle-jiao and qi, invigorate spleen and benefit lung, and is used for treating spleen-lung weakness, poor appetite and loose stool; the bighead atractylodes rhizome can invigorate the spleen and replenish qi, is used for treating spleen deficiency and anorexia, and is a common traditional Chinese medicine for tonifying the spleen and qi. The formula is prepared by the compatibility of the five medicinal materials, and achieves the effect of promoting digestion by promoting digestion and relieving stasis, strengthening spleen and replenishing qi, nourishing stomach and stimulating appetite, enhancing gastric motility, promoting gastrointestinal evacuation and the like, so the formula is scientifically prepared by selecting medicinal materials which are both edible and medicinal and can be used as health-care food and are issued by the state bureau according to the mechanism of dyspepsia by applying the theories of traditional Chinese medicine and modern medicine. The formula has definite function, no incompatibility, is safe and effective to eat, and can play a good role in health care.
The 5 traditional Chinese medicines of the product are prepared into chewable tablets by combining the modern technology of extraction and concentration, the traditional Chinese medicine water extract is bitter and astringent when directly taken and has gritty feel, and if the traditional Chinese medicine water extract is directly prepared into a dosage form, the compliance of a user is poor. In the invention, the types, the proportion and the proportion of the using amount of the auxiliary materials are preferably obtained through a plurality of experimental researches, so that the problem of bitter and astringent taste after the chewing tablets prepared from the traditional Chinese medicine extract are often eaten, namely, the chewing tablets do not feel greasy, and the prepared tablets have good chewing feeling, are sour, sweet, delicious and beautiful in appearance. In addition, the chewable tablet prepared from the composition has the health-care function of promoting digestion proved by human body function experiments.
Detailed Description
As mentioned above, the invention aims to provide a composition with dual purposes of medicine and food and having the function of promoting digestion, and a preparation method and application thereof. The following will specifically describe the contents of the experimental examples.
If the specific conditions are not indicated, the method is carried out according to the conventional conditions or the conditions suggested by manufacturers, and the used raw material medicines or auxiliary materials and the used reagents or instruments are the conventional products which can be obtained commercially.
It is particularly pointed out that the present invention is described in more detail below by means of specific embodiments in order to be able to better understand the solution of the invention and the advantages of its various aspects. The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention.
Example 1 screening of pharmaceutical excipients having digestion promoting efficacy
Weighing 5 parts of hawthorn, 5 parts of malt, 5 parts of bighead atractylodes rhizome, 2 parts of radix pseudostellariae and 2 parts of dried orange peel, weighing the five medicinal materials according to the formula, adding 10 times of water, decocting and extracting for 2 times, each time for 1 hour, filtering, combining extracting solutions, concentrating under reduced pressure at 70 +/-5 ℃, concentrating to relative density of 1.8-1.12 (60 +/-5 ℃), performing spray drying, crushing spray-dried powder, and sieving with a 80-mesh sieve to obtain the dry paste powder.
Mixing the above dry extract powder with adjuvants, making soft mass with 90% ethanol, granulating with 16 mesh sieve, drying, grading, adding lubricant into the obtained granule, mixing, and tabletting.
1. Adjuvant screening protocol
The variety and the approximate dosage of the added auxiliary materials are determined by adopting a single-factor test, and then the problems which are difficult to quantify or are fuzzy can be digitalized by the fuzzy evaluation through an orthogonal test and a fuzzy evaluation method, and the accurate and reliable optimal process can be screened out by the result obtained by the fuzzy evaluation of a multi-factor horizontal test set by the orthogonal test.
2. Single factor test
2.1 Diluent screening
The dry paste powder in example 1 is bitter and astringent, so a diluent is required to be added to mask bitter taste and improve granulation and tabletting effects, and the influence of auxiliary materials such as microcrystalline cellulose, starch, dextrin, maltodextrin, powdered sugar, lactose and the like on granulation, tabletting and taste is mainly considered, wherein the addition amount accounts for 30% of the total weight.
Table 1 filler investigation
According to the results of diluent investigation in table 1, and the combination of the tissue morphology of the chewable tablet, the granulation and tabletting effects of the microcrystalline cellulose are the best, the chewing feeling of the product is good, the product does not stick to teeth, and the friability is lower than 1%.
2.2 taste-modifying agent screening
After 30% of microcrystalline cellulose is added into the dry paste in the embodiment, the granulation effect and the tabletting effect are good, but the taste is slightly bitter, the best chewing state is not achieved, the chewable tablet with better taste can be obtained under the condition of adding the sweetening agent and the sour agent, the influence of different sweetening agents and sour agents on the taste of the chewable tablet is mainly considered for enabling the chewable tablet to be sour, sweet and delicious, and as a result, the dry paste with better taste is respectively citric acid and stevioside, and the result is shown in table 2.
TABLE 2 taste-modifying agent screening
2.3 Lubricant screening
The proper amount of lubricant is added into the granulated particles, so that the appearance of the chewable tablet is smooth and complete, and the talc powder, the magnesium stearate and the silicon dioxide are mainly considered, and as a result, the effect of the magnesium stearate is optimal.
3. Design of orthogonal experiments
On the basis of a single-factor test, the influence of the addition amounts of stevioside, citric acid, microcrystalline cellulose and magnesium stearate relative to dry paste powder on the sensory evaluation of the chewable tablets is respectively considered, and the levels of all factors are shown in table 3.
TABLE 3 levels of orthogonal experimental factors
4. Fuzzy mathematic model building
4.1 evaluation personnel selection and evaluation method
10 food professionals, 5 men and 5 women and the panelists are healthy, have no bad hobbies such as alcohol addiction, tobacco addiction and the like, can independently evaluate and analyze the sensory indexes of the chewable tablets, and give reasonable scores according to different formulas of the chewable tablets.
4.2 sensory evaluation criteria
According to the characteristics of the product, the sensory evaluation standard of the product is determined to be composed of four factors of color, texture, mouthfeel and chewiness, namely X ═ color, texture, mouthfeel and chewiness.
Panelists gave scores for chewable tablets of different formulations according to established sensory evaluation criteria, see table 4 for reference.
TABLE 4 sensory evaluation criteria
4.3 determination of the weighting coefficients
The product determines the color, the form, the tissue structure and the taste and smell as main sensory evaluation indexes, the weight distribution scheme aims to reflect the importance reaction degree of four factors, and when the sensory evaluation is carried out on the taste-comfortable chewable tablet, the weight of the color, the form, the tissue structure and the taste and smell is determined by adopting a forced decision method and a binary comparison decision method. Selecting 10 panelists in different age groups, comparing the factors of the flavor-soothing chewable tablets in evaluation one by one, wherein the important factor is 1 point, the secondary factor is 0 point, the self comparison is 1 point, and the weight distribution is shown in table 5.
TABLE 5 sensory evaluation weight distribution
The total score of 10 members was 100, the specific gravity of the four evaluation factors and the total score was the weight, the weight of each factor was represented by the letter K, and K ═ K (K) was calculated1，K2，K3，K4)＝(0.15，0.20，0.35，0.30)
5. Results and analysis
5.1 establishing fuzzy comprehensive evaluation mathematic model
5.1.2 establishing a fuzzy evaluation matrix
According to the orthogonality test Table L9(34) The middle combination is tested to prepare 9 groups of flavor-soothing chewable tablet samples, 10 panelists respectively score the color, the tissue form, the mouthfeel and the chewiness of the chewable tablets, and the evaluation results are shown in table 6.
TABLE 6 sensory evaluation results of different formulations
Dividing the data of 9 groups of experiments by 10 people to obtain 9 fuzzy evaluation matrixes which respectively correspond to No. 1-9 experiments, wherein for example, the fuzzy matrix of the No. 1 sample is as follows:
the same can be obtained:
according to the fuzzy change principle, fuzzy calculation is carried out on data in the matrix by using a membership function, and the comprehensive membership degree Y of each sample to evaluation factors is calculated to be K multiplied by R, such as:
the same can be obtained:
Y2＝(0.375，0.33，0.225，0.07)，Y3＝(0.24，0.225，0.22，0.315)，
Y4＝(0.495，0.27，0.235，0)，Y5＝(0.675，0.225，0.1，0)，
Y6＝(0.265，0.295，0.41，0.03)；Y7＝(0.285，0.315，0.315，0.085)
Y8＝(0.31，0.29，0.335，0.065)，Y9＝(0.175，0.22，0.33，0.275)。
5.1.3 fuzzy evaluation Total score calculation
The four evaluation grades of excellence, goodness, middle and difference of each factor correspond to scores of 90, 80, 70 and 60. And multiplying the comprehensive evaluation results by corresponding scores respectively and adding the scores to obtain the final total score of each sample. Such as: the final sensory score of sample No. 1 was 0.13 × 90+0.14 × 80+0.385 × 70+0.345 × 60 and 70.55 ═ g
The calculation methods of nos. 2 to 9 are the same, and the results of orthogonality are shown in table 7.
TABLE 7 results of comprehensive evaluation of orthogonal test
The experiment adopts a range analysis method, the range reflects the influence degree of each factor on the sensory evaluation of the chewable tablets, and the influence factors are citric acid > stevioside > microcrystalline cellulose > magnesium stearate in the range of the magnitude, and the optimal combination is A2B2C3D2, namely 2% of citric acid, 1% of stevioside, 40% of microcrystalline cellulose and 1% of magnesium stearate are added.
5.2 validation test
Three sets of validation tests were performed on combination number A2B2C3D2 according to the above test procedure, in combination with the fuzzy evaluation test and orthogonal test results, and scored, the results are shown in table 8.
Table 8 shows the results of the test
Therefore, the screening result according to the test scheme is used as the preparation scheme of the product, the process is stable and reliable, and the scale-up production can be realized.
Example 2 digestion promoting function human eating trial
Mixing the dry extract powder prepared in the example 1 with 2% of citric acid, 1% of stevioside and 40% of microcrystalline cellulose, wherein the citric acid needs to be crushed, and sieving the crushed citric acid by a 80-mesh sieve. Making soft material with 90% ethanol, granulating with 16 mesh sieve, drying, grading, adding 1% magnesium stearate into the obtained granules, mixing, and tabletting to obtain the chewable tablet.
1. General conditions
The sample prepared in example 2 was used as a test substance to conduct a human feeding test. The test subjects were included in 112 cases, and were randomly divided into a test diet group and a control group, and 3 cases of the test diet group and 3 cases of the control group were excluded during the test, 106 cases of the actual test subjects, 53 cases of the test diet group, and 53 cases of the control group. See table 9 for details.
TABLE 9 comparison of age, sex, course of disease and clinical symptom balance in the two groups before eating trial
Comparison between pre-treatment groups P >0.05
As can be seen from Table 9, the age, sex, course and clinical symptoms of the pre-test groups were not significantly different from those of the control group (P > 0.05). The results show that the age, sex, course and clinical symptoms of the two groups before eating the test are balanced and comparable.
The subjects were asked to investigate their mental, sleep, diet and urine conditions, and counted on a good, normal and differential scale, and their blood pressure and heart rate were measured, the results are shown in Table 10.
TABLE 10 comparison of general conditions of two groups before and after test
As can be seen from Table 10, most subjects had good general condition, and before and after the test, the subjects had normal mental, sleep, diet and urination. Compared with the two groups of subjects before and after the test eating, all index differences have no significance (P is more than 0.05), which shows that the chewable tablets have no adverse effect on the general condition of the human body after the test eating.
2. Safety index observation
2.1 routine changes of blood, urine and feces before and after eating test
TABLE 11 routine changes of blood, urine and feces before and after eating test
From table 11, it can be seen that the blood routine of the two groups of subjects is in the normal range, and the comparison difference between the two groups before and after the test feeding is not significant (P > 0.05); the two groups of subjects had normal urine and normal stool before and after the routine test.
2.2 Biochemical indicators of blood and changes of liver and kidney function before and after eating
TABLE 12 Change in Biochemical index of blood before and after eating trial
Table 12 shows that the blood biochemical indicators for both groups of subjects were within the normal range; and the comparison difference between the two groups before and after the test feeding is not significant (P is more than 0.05). The results show that the product prepared by the invention has no adverse effect on the physical health of the testee.
2.3 chest X-ray, electrocardiogram and B-ultrasonic examination of abdomen
The chest X-ray, electrocardiogram and B-ultrasonic examination of abdomen of the subject are all within normal range.
3. Observation of efficacy index
3.1 comparison of the degree of gastrointestinal symptoms in the two groups before tasting
TABLE 13 comparison of degree of gastrointestinal symptoms in the pre-test group with the control group
() Internal control group data
As can be seen from Table 13, there was no significant difference in the degree of gastrointestinal symptoms between the pre-test group and the control group (P > 0.05).
3.2 improvement of gastrointestinal symptoms after eating trial
TABLE 14 comparison of gastrointestinal symptom levels in the post-test group and the control group
() Internal control group data
TABLE 15 improvement of gastrointestinal symptoms after test feeding
() Internal control group data
As can be seen from Table 15, the improvement of abdominal pain, belching, acid regurgitation, abdominal distention, appetite, diarrhea or constipation after eating the trial group was significantly different from that of the control group (P < 0.001).
3.3 score statistics of clinical symptoms before and after the test
TABLE 16 statistics of the integral of clinical symptoms of two groups before and after a test meal
Self-comparison ## P <0.001, and inter-comparison ## P <0.001
As can be seen from Table 16, the clinical symptom scores of the two groups before test feeding have no significant difference, the clinical symptom scores of the test feeding group after the test feeding are obviously lower than those of the control group, and the difference is significant (P is less than 0.001); compared with the test group, the clinical symptom score after the test feeding is significantly different from that before the test feeding (P is less than 0.001).
3.4 Change in gastric/intestinal motility before and after eating trial
The evacuation rate of 20 barium bars from the stomach at 3 hours was used as an index reflecting the gastric/intestinal motility of the subjects. The results of the gastric emptying tests before and after the test are shown in Table 17.
TABLE 17 gastric emptying before and after test feedingResults of rate measurement
Self-comparison # P <0.001, inter-comparison # P <0.01
As can be seen from Table 17, there was no significant difference in gastric emptying rate between the two groups before the test feeding, and the gastric emptying rate after the test feeding was significantly greater than that of the control group, and the difference was significant (P < 0.01); compared with the test-feeding group, the gastric emptying rate after test feeding is obviously greater than the difference before test feeding, and the difference is significant (P is less than 0.001).
4. Loss rate of subject
The test subjects comprise 112 cases, 56 cases of test food groups and 56 cases of control groups, 3 cases of test food groups and 3 cases of control groups are not reviewed at the specified time, the test food groups meet the exclusion standard of the subjects, and 53 cases of effective test food groups and 53 cases of control groups of the subjects. The loss rates of the subjects in the test group and the control group are 5.4 percent and 5.4 percent respectively.
5. Observation of adverse reactions
No allergy and other adverse reactions are seen.
TABLE 18 post-test two groups had allergies and other adverse reactions during the test period
According to the judgment standard of the human body eating trial test for promoting the digestion function in the technical Specification for health food inspection and evaluation (2003 edition), the result shows that the chewable tablet of the invention has the digestion promoting function.
Finally, it should be noted that: it should be understood that the above examples are only for clearly illustrating the present invention and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the scope of the invention.
Claims (10)
1. A composition having digestion promoting function, wherein the composition comprises by weight: 1-10 parts of hawthorn, 1-15 parts of malt, 1-10 parts of bighead atractylodes rhizome, 1-15 parts of dried orange peel and 1-10 parts of radix pseudostellariae.
2. The composition as claimed in claim 1, wherein said composition comprises: 3-7 parts of hawthorn, 3-7 parts of malt, 3-7 parts of bighead atractylodes rhizome, 1-5 parts of dried orange peel and 1-5 parts of radix pseudostellariae.
3. The composition of claim 1, wherein the traditional Chinese medicine composition comprises, by weight: 5 parts of hawthorn, 5 parts of malt, 5 parts of bighead atractylodes rhizome, 2 parts of dried orange peel and 2 parts of radix pseudostellariae.
4. Use of the composition of any one of claims 1 to 3 for the preparation of a medicament, health product or food having digestive function promoting effect.
5. A pharmaceutical, nutraceutical or food product comprising a composition according to any of claims 1 to 3.
6. The drug, health product or food according to claim 5, wherein the adjuvant in the drug, health product or food comprises sucrose, mannitol, sorbitol, dextrin, magnesium stearate, lactose, microcrystalline cellulose, starch, white granulated sugar, xylitol, sucralose, or stevioside.
7. The drug, health product or food of claim 5, wherein the excipient is selected from the group consisting of microcrystalline cellulose, stevioside, citric acid and magnesium stearate.
8. The medicine, health product or food according to claim 7, wherein the weight ratio of the composition, the microcrystalline cellulose, the stevioside, the citric acid and the magnesium stearate is preferably 50-70: 10-50: 0.5-2: 1-5: 0.5 to 2, more preferably 56 or 40: 1: 2: 1.
9. a process for preparing a composition as claimed in any one of claims 1 to 3, wherein the hawthorn fruit, malt, white atractylodes rhizome, dried orange peel and pseudostellaria root are decocted in water for extraction, filtered and the concentrated solution is spray dried.
10. The preparation method of the medicine, the health-care product or the food is characterized in that when the medicine, the health-care product or the food is a tablet, the preparation method comprises the following steps:
weighing 5 parts of hawthorn, 5 parts of malt, 5 parts of bighead atractylodes rhizome, 2 parts of radix pseudostellariae and 2 parts of dried orange peel according to the formula, adding 10 times of water, decocting and extracting for 2 times, each time for 1 hour, filtering, combining extracting solutions, concentrating under reduced pressure at 70 +/-5 ℃, concentrating to relative density of 1.8-1.12 at 60 +/-5 ℃, spray drying, crushing spray-dried powder, and sieving by a 80-mesh sieve to obtain dry paste powder;
mixing the dry extract powder with 2% citric acid, 1% stevioside and 40% microcrystalline cellulose, making soft mass with 90% ethanol, granulating with 16 mesh sieve, drying, grading, adding 1% magnesium stearate into the obtained granule, mixing, and tabletting.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911229074.1A CN110934971A (en) | 2019-12-04 | 2019-12-04 | Composition with digestion promoting function and preparation method and application thereof |
| PCT/CN2020/094730 WO2021109510A1 (en) | 2019-12-04 | 2020-06-05 | Composition having digestion promoting function, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911229074.1A CN110934971A (en) | 2019-12-04 | 2019-12-04 | Composition with digestion promoting function and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110934971A true CN110934971A (en) | 2020-03-31 |
Family
ID=69908847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911229074.1A Pending CN110934971A (en) | 2019-12-04 | 2019-12-04 | Composition with digestion promoting function and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110934971A (en) |
| WO (1) | WO2021109510A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111685322A (en) * | 2020-06-18 | 2020-09-22 | 汤臣倍健股份有限公司 | Composition for promoting gastric digestion and health-care product and application thereof |
| WO2021109510A1 (en) * | 2019-12-04 | 2021-06-10 | 江苏康仁医药科技开发有限公司 | Composition having digestion promoting function, preparation method and application thereof |
| CN115737766A (en) * | 2022-12-28 | 2023-03-07 | 广东好味鲜菜品与营养研究所 | Composition for promoting digestion and preparation method of granular preparation of composition |
| CN115919975A (en) * | 2022-12-28 | 2023-04-07 | 广东好味鲜菜品与营养研究所 | Composition for promoting digestion and preparation method of beverage thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056178A (en) * | 2014-07-10 | 2014-09-24 | 海南医学院 | Traditional Chinese medicine combination with digestion-improving function and application thereof |
| CN104489656A (en) * | 2014-12-07 | 2015-04-08 | 阿拉善盟万铭生物制品有限公司 | Cynomorium songaricum flavone chewable tablets and preparation method thereof |
| CN107307400A (en) * | 2017-06-27 | 2017-11-03 | 江苏康缘药业股份有限公司 | It is a kind of that there is composition of promotion digestive function and preparation method thereof |
| CN107495366A (en) * | 2017-08-17 | 2017-12-22 | 内蒙古兰太药业有限责任公司 | There is the Ricipe for health care food of assistant protection function to gastric mucosa damage |
| CN109170874A (en) * | 2018-11-19 | 2019-01-11 | 威宁县品鲜食品有限公司 | A kind of stomach strengthening function food compositions and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110934971A (en) * | 2019-12-04 | 2020-03-31 | 江苏康缘药业股份有限公司 | Composition with digestion promoting function and preparation method and application thereof |
-
2019
- 2019-12-04 CN CN201911229074.1A patent/CN110934971A/en active Pending
-
2020
- 2020-06-05 WO PCT/CN2020/094730 patent/WO2021109510A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056178A (en) * | 2014-07-10 | 2014-09-24 | 海南医学院 | Traditional Chinese medicine combination with digestion-improving function and application thereof |
| CN104489656A (en) * | 2014-12-07 | 2015-04-08 | 阿拉善盟万铭生物制品有限公司 | Cynomorium songaricum flavone chewable tablets and preparation method thereof |
| CN107307400A (en) * | 2017-06-27 | 2017-11-03 | 江苏康缘药业股份有限公司 | It is a kind of that there is composition of promotion digestive function and preparation method thereof |
| CN107495366A (en) * | 2017-08-17 | 2017-12-22 | 内蒙古兰太药业有限责任公司 | There is the Ricipe for health care food of assistant protection function to gastric mucosa damage |
| CN109170874A (en) * | 2018-11-19 | 2019-01-11 | 威宁县品鲜食品有限公司 | A kind of stomach strengthening function food compositions and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021109510A1 (en) * | 2019-12-04 | 2021-06-10 | 江苏康仁医药科技开发有限公司 | Composition having digestion promoting function, preparation method and application thereof |
| CN111685322A (en) * | 2020-06-18 | 2020-09-22 | 汤臣倍健股份有限公司 | Composition for promoting gastric digestion and health-care product and application thereof |
| CN115737766A (en) * | 2022-12-28 | 2023-03-07 | 广东好味鲜菜品与营养研究所 | Composition for promoting digestion and preparation method of granular preparation of composition |
| CN115919975A (en) * | 2022-12-28 | 2023-04-07 | 广东好味鲜菜品与营养研究所 | Composition for promoting digestion and preparation method of beverage thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021109510A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110934971A (en) | Composition with digestion promoting function and preparation method and application thereof | |
| KR100937455B1 (en) | Bowel movement promotion functional food containing psyllium seed, rice bran fermentation extracts and yeast extracts and manufacturing method thereof | |
| CN101253988B (en) | Health food with moistening sausage defaecate function and its preparation | |
| CN107518384A (en) | A kind of composition and preparation method thereof | |
| CN107518383A (en) | A kind of composition and preparation method thereof | |
| CN107183705A (en) | A kind of relax bowel improves the functional food of constipation | |
| CN108543020A (en) | A kind of medicinal health-care preparation and preparation method thereof for improving sleep | |
| CN107518259A (en) | A kind of food and preparation method thereof | |
| CN101601827A (en) | A kind of Chinese medicine preparation that prevents and/or treats dry syndrome, slow down aging | |
| CN107518260A (en) | A kind of food and preparation method thereof | |
| CN101579119A (en) | Nutritional food with function of relaxing bowel and preparation method thereof | |
| CN1090951C (en) | Traditional Chinese medicine for curing gastrointestinal disease | |
| CN103816278B (en) | Composition for reducing blood sugar and application thereof | |
| CN104431772A (en) | Flour-made food capable of lubricating intestines and detoxifying and preparation method of flour-made food | |
| CN107307033A (en) | A kind of biscuit with the aid digestion effect of strengthening the spleen and stomach and preparation method thereof | |
| CN101352552B (en) | Capsules for promoting children's intelligence, growth and development | |
| CN103933453A (en) | Medicine composition for treating dyspepsia-induced damp stagnation | |
| CN107375690A (en) | A kind of turbid hypoglycemic of invigorating the spleenization dissipate and preparation method and application | |
| CN105770705A (en) | Medicinal preparation for treating functional dyspepsia of children and application of medicinal preparation | |
| CN101623365B (en) | Tuckahoe spleen-strengthening granules and preparation method thereof | |
| CN104383423A (en) | Traditional Chinese medicine for treating anorexia | |
| CN104940332B (en) | A kind of Fructooligosaccharidcomposition composition and preparation method thereof of defaecation and reduction flatulence | |
| CN110384782A (en) | It is a kind of to intervene the Chinese medicine composition of phlegm-dampness constitution, broken wall composition and preparation method thereof | |
| CN104324113A (en) | Drug for treatment of irritable bowel syndrome and preparation method thereof | |
| CN110801010A (en) | Composition and health food for preventing and treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40025755 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200331 |
|
| RJ01 | Rejection of invention patent application after publication |